Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced it has been awarded a three-year supplier contract with Premier Purchasing Partners, L.P., the group purchasing unit of the Premier healthcare alliance, for its radiopharmaceutical imaging agents. Effective January 1, 2012 through December 31, 2014, the new radiopharmaceutical products agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), Gallium 67 (Gallium Citrate Ga67 Injections), Neurolite® (Kit of the Preparation of Technetium Tc99m Bicisate for Injection), TechneLite® (Technetium Tc99m Generator), 201 Thallium (Thallous Chloride Tl201 Injection) and Xenon 133 (Xenon Xe 133 Gas).
“We are excited to announce that Premier has awarded Lantheus with a three-year supplier agreement for our nuclear imaging products”
Lantheus' radiopharmaceutical products will be offered through a specially negotiated contract to more than 2,500 hospitals nationwide and 76,000-plus healthcare sites. The contract was awarded after a competitive bidding process that examined multiple factors, including pricing and clinical experience with the diagnostic imaging agents, as well as Lantheus' support of the products.
"We are excited to announce that Premier has awarded Lantheus with a three-year supplier agreement for our nuclear imaging products," said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging. "These important agents are critical to helping clinicians assess patients for cardiac disease, stroke, cancerous tumors and pulmonary function. We are pleased that, once again, Premier has selected Lantheus as a preferred supplier to its members."
Scientists reveal how miRNAs shape cancer and offer new paths for treatment